2018 - 2 Issue

Original article

One-year follow-up outcomes of treatment of wet age-related macular degeneration with aflibercept

Yun Min Klimešová ORCID
Martin Penčák ORCID – Zbyněk Straňák ORCID – Lucia Lalinská – Miroslav Veith ORCID

Full Text links

DOI: 10.31348/2018/1/1-2-2018

Published in Czech and Slovak Ophtalmology: 2018 - 2

Published on website: 23.08.2018

Keywords: aflibercept, anti-VEGF therapy, optical coherence tomography (OCT), wet AMD

Summary

Purpose: To evaluate one-year follow-up outcomes of the treatment with aflibercept in patients with newly diagnosed wet age-related macular degeneration (AMD).

Methods: It was a retrospective analysis of 28 eyes of 28 patients with an average age of 74,2 years, who were treated with aflibercept at the Department of Ophthalmology,
University Hospital Královské Vinohrady in Prague. All patients were treated according to the SPC, it means initial 3 injections at monthly intervals, followed by 4 injections every 2 months. We evaluated the change in the best corrected visual acuity (BCVA) on Early Treatment of Diabetic Retinopathy Study (ETDRS) charts and the change in central retinal thickness (CRT) by the optical coherence tomography (OCT).

Results: The mean input visual acuity was 61,5 letters of the ETDRS optotype. After the initial 3 injections the BCVA improved to 70,5 letters and after one year‘s treatment,
it dropped slightly to 68,1 letters. Better or equal visual acuity had 25 eyes (89,3 %), with worsening in 3 eyes (10,7 %). CRT decreased from an entry average of 360,9 μm to
253,3 μm after the initial phase and to 233,8 μm after one year treatment. No signs of disease activity had 25 eyes (89,3 %) at the end of the follow-up period. There were no
complications of the treatment.

Conclusion: In our study, we confirm the efficacy and safety of aflibercept in patients with newly diagnosed wet AMD. Following the fixed treatment regimen we can achieve
similarly excellent outcomes in real clinical practice as in clinical trials.

References

  1. Ambati, J., Fowler, BJ.: Mechanisms of age-related macular degeneration. Neuron, 75; 2012: 26-39.
  2. Arcinue, CA., Ma, F., Barteselli, G. et al.: One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. Am J Ophthalmol, 159; 2015: 426 – 436.
  3. AREDS Research Group: Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Numer 3. Ophthalmology, 107; 2000: 2224–2232.
  4. Bakall, B., Folk, JC., Boldt, HC. et al.: Aflibercept therapy for exudative age -related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol, 156; 2013: 15–22.
  5. Balaratnasingam, C., Dhrami-Gavazi, E., McCann, JT. et al.: Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration. Clin Ophthalmol, 19; 2015: 2355 – 71.
  6. Brown, MM., Brown, GC., Stein, JD. et al.: Age-related macular degeneration: economic burden and value-based medicine analysis. Can J Ophthalmol, 40; 2005: 277 - 87. -related macular degeneration. N Engl J Med, 351; 2004: 2805–16.
  7. Brown, DM., Michels, M., Kaiser, PK. et al.: Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology, 116; 2009: 57–65.
  8. Dixon, JA., Olivek, S. C., Olson, JL. et al.: VEGF trap-eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs . 18; 2009: 1573–1580.
  9. Ernest, J.: Makulární degenerace: Trendy v léčbě věkem podmíněné makulární degenerace. Praha: Mladá fronta, 2010. (ISBN 978-80-204-2363-4) 249s.
  10. Friedman, DS., O’Colmain, BJ., Munoz, B. et al.: Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol, 122;2004: 564–572.
  11. Gharbiya, M., Iannetti, L., Parisi, F. et al.: Visual and anatomical outcomes of intravitreal aflibercept for treatment -resistant neovascular age-related macular degeneration. Biomed Res Int, 2014;2014:273754.
  12. Gragoudas, ES., Adami, AP., Cunningham, ET. et al.: VEGF Inhibition Study in Ocular Neovascular Clinical Trial Group. Pegaptanib for neovascular age
  13. Grisanti, S., Tatar, O.: The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res , 27; 2008: 372–390.
  14. Heier, JS., Brown, DM., Chiny, V. et al.: Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. Ophthalmology, 119;2012: 2537– 2548.
  15. Hyman, L., HE, O., Grimson, E. et al. Risk factors for age related maculopathy. Incest Ophthalmol Vis Sci, 33; 1992: 801.
  16. Chrapek, O., Jarkovský, J., Studnička, J. et al.: The efficacy of ranibizumab treatment in clinical practice in patients with the wet form of age-related macular degeneration. The results of the Czech National Registry. Biomedical Papers – Olomouc 2015; 159(3): 407-412.
  17. Chrapek, O., Pitrová, Š., Dušek, L. et al.: Výsledky léčby vlhké formy věkem podmíněné makulární degenerace u pacientů evidovaných v celonárodním registru AMADEUS. Česká a slovenská oftalmologie 2010, 66(3):110-118.
  18. Jo, N., Mailhos, C., Ju, M. et al.: Inhibition of platelet-derived growth factor B signaling enhances the efficacy of
  19. Kolář, P.: Věkem podmíněná makulární degenerace. Praha: Grada Publishing, a.s., 2008. (ISBN 978-80-247-6760-4) 148s.
  20. Messenger, WB., Campbell, JP., Faridi, A., et al.: Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration. Br J Ophthalmol, 98; 2014:1205–1207.
  21. Neufeld, G., Cohen, T., Gengrinovitch S. et al.: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J., 13; 1999: 9–22.
  22. Rakic, JM., Lambert, V., Devy, L. et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Incest Ophthalmol Vis Sci , 44; 2003: 3186 – 3193.
  23. Rosenfeld, PJ., Brown, DM., Heier, JS. et al.: Ranibizumab for neovascular age -related macular degeneration. N Engl J Med, 355; 2006: 1419 – 1431.
  24. Salomon, SD., Lindsley, K., Vedula, SS. et al.: Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2014; 8: CD005139
  25. Schmidt-Erfurth, U., Kaiser, PK., Korobelnik, J-F. et al.: Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration. Ophthalmology, 121; 2014: 193–201.
  26. Semeraro, F., Morescalchi, F., Duse, S. et al.: Aflibercept in wet AMD: specific role and optima use. Drug Des Devel Ther, 7; 2013: 711–722.
  27. Singerman, LJ., Masonson, H., Patel, M. et al.: Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol, 92; 2008: 1606–1611. anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol , 168; 2006: 2036–2053.
  28. Studnička, J., Říhová, B., Rencová, E. et al.: Cost and effectiveness of therapy for wet age-related macular degeneration in routine clinical practice. Ophthalmologica 2013; 230(1): 34-42.
  29. Udaondo, P., Salom, D., García- Delpech, S. et al.: Aflibercept as First- Line Therapy in Patients with Treatment-Naïve Neovascular Age-Related Macular Degeneration: Prospective Case Series Analysis in Real-Life Clinical Practice., 236; 2016: 29-35.
  30. Warwick, AN., Leaver, HH., Lotery, AJ.: Fixed bimonthly aflibercept in naïve and switched neovascular age-related macular degeneration patients: one year outcomes. Int J Ophthalmol, 9; 2016: 1156–1162.
  31. Wykoff, CC., Brown, DM., Maldonado, ME. et al.: Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial) Br J Ophthalmol, 98; 2014: 951–955.